Mednax, Inc (NYSE:MD) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.80-0.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.85.
Mednax (NYSE:MD) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting the consensus estimate of $0.87. The firm had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.09 earnings per share.
Several brokerages have recently commented on MD. Jefferies Group LLC reaffirmed a hold rating and set a $44.00 price objective on shares of Mednax in a research note on Friday. Mizuho reaffirmed a neutral rating and set a $48.00 price objective (down from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. KeyCorp raised shares of Mednax from a sector weight rating to an overweight rating and set a $51.00 price objective for the company in a research note on Sunday, September 17th. BidaskClub downgraded shares of Mednax from a hold rating to a sell rating in a research note on Friday, July 28th. Finally, Robert W. Baird reaffirmed a hold rating and set a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $55.22.
In related news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2017/11/03/mednax-inc-md-updates-q4-earnings-guidance.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
What are top analysts saying about Mednax Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mednax Inc and related companies.